CytoSorbents Corporation · NASDAQ:CTSO
CytoSorbents — Investor Presentation (February 2019)
33 slides from CytoSorbents's investor presentation, February 2019
Slide 1: Investor Presentation February 2019
HELPING REDUCE DEADLY UNCONTROLLED INFLAMMATION IN HOSPITALIZED PATIENTS WORLDWIDE NASDAQ: CTSO Investor Presentation February 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future re
Slide 3: CytoSorbents is a Leader in Critical Care Immunotherapy
CytoSorbents is a Leader in Critical Care Immunotherapy Leading the Prevention or Treatment of Life-Threatening Inflammation in the ICU and Cardiac Surgery using CytoSorb® Blood Purification 3
Slide 4: CytoSorbents At a Glance
CytoSorbents At a Glance (NASDAQ: CTSO $8) • CytoSorb® is E.U. approved as an extracorporeal cytokine adsorber with 56,000+ cumulative treatments (up from 35,000 a year ago) delivered and distributed in 55 countries • Record 2018 Financial Performance: 2017 2018* Increase Total Revenue $15.1M $22.3M
Slide 5: Leadership Background
Leadership Background Phillip Chan, MD, PhD – Chief Executive Officer and President Former Partner at the $80M NJTC Venture Fund, leading life science investments for 5 years. Co-founder of Andrew Technologies, commercializing its HydraSolve™ lipoplasty device in the U.S. MD/PhD from Yale School of
Slide 6: Product Pipeline
Product Pipeline CytoSorb-XL HemoDefend Blood Sepsis, Transfusions Critical Care, High Risk Surgery Sepsis, Critical Care, High Risk Nearing US Pivotal Trial Surgery CE Mark Approved ContrastSorb DrugSorb K+ontrol K+ CT Imaging, Drug Overdose, Severe Interventional Chemo Hyperkalemia Radiology Remov
Slide 7: Uncontrolled Inflammation is Deadly
Uncontrolled Inflammation is Deadly Sepsis Trauma Influenza Burn Injury Millions Die Of Uncontrolled Deadly Inflammation Each Year Lung Injury Cytokine Release Syndrome Pancreatitis Liver Failure Surgical Complications 7
Slide 8: Massive Inflammation Causes Organ Failure
Massive Inflammation Causes Organ Failure Organ failure occurs when vital organs stop working, causing nearly half of all deaths in the ICU. Little can be done to prevent or treat organ failure today 8
Slide 9: No Ideal Options to Treat Severe Inflammation
No Ideal Options to Treat Severe Inflammation Anti-Inflammatory Immunosuppressive (too weak) (too strong) NSAIDs Corticosteroids Aspirin Chemotherapy Organ transplant Anti-cytokine Anti-rejection drugs antibodies Radiation Anti-integrin antibodies Immune system ablation Anti-oxidants Anti-leukocyte
Slide 10: CytoSorb Bridges the Gap
CytoSorb Bridges the Gap Anti-Inflammatory Immunosuppressive (too weak) (too strong) NSAIDs Corticosteroids Aspirin Chemotherapy Anti-cytokine Organ transplant antibodies Anti-rejection drugs Anti-integrin Radiation antibodies Immune system Anti-oxidants ablation Anti-leukocyte Abs 10
Slide 11: CytoSorb Reduces the Fuel to the Fire
CytoSorb® Reduces the Fuel to the Fire • CytoSorb® targets the $20+ billion opportunity in critical care and cardiac surgery • Approved in the European Union as the first specifically approved extracorporeal cytokine adsorber • Broad indication for use where cytokines are elevated • Removes cytokine
Slide 12: Patented Blood Purification Technology
Patented Blood Purification Technology The underlying blood purification technology is based on biocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood Each bead is about the size of a grain of salt . • Proprietary patented technology with multip
Slide 13: CytoSorb Is Active in Cytokine Sweet Spot
® ® CytoSorb CytoSorbIs Active Active in in Cytokine Cytokine Sweet Sweet Spot Spot IL-1a TNF-α monomer Pancreatic Trypsin IFN-γ monomer Toxic Shock Syndrome Toxin IL-1Ra IL-18, Pancreatic Chymotrypsin Myoglobin HMGB1 Procalcitonin TGF-β TNF-α trimer MCP-1 IL-6 Pneumolysin toxin IL-13 sFas ligand Pa
Slide 14: CytoSorb Reduces Inflammatory Mediators Broadly
CytoSorb Reduces Inflammatory Mediators Broadly CytoSorb can treat hyperinflammation by reducing a broad range of proinflammatory: • Cytokines • Pathogen associated molecular patterns (PAMPs) • Damage associated molecular patterns (DAMPs) 14
Slide 15: CytoSorb is "Plug and Play"
CytoSorb is “Plug and Play” Compatible with Existing Dialysis and Heart-Lung Machines • Place a temporary dialysis catheter in a major vein • Connect the device to a standard dialysis, ECMO, or heart-lung machine found in hospitals worldwide • Pump blood out of the body and through the cartridge • T
Slide 16: Goal: To Prevent or Treat Organ Failure
Goal: To Prevent or Treat Organ Failure Improve Decrease Patient Costs Of Outcome ICU and and Patient Survival Care Sepsis ARDS Burn Injury Trauma Pancreatitis Influenza Surgical The Potential to Revolutionize Critical Care Medicine 16
Slide 17: Refractory Septic Shock
Refractory Septic Shock Prospective, single arm study in 20 patients with refractory late-stage septic shock using CytoSorb aggressively every 12 hours with a new cartridge • Patients had refractory shock despite high doses of vasopressors, respiratory failure requiring mechanical ventilation, oligo
Slide 18: The World Needs CytoSorb
The World Needs Cyto Tor Sepals Appear to Be Rising Dramatically ‘as a Global Health ity — Len >= a) ‘1 AmericaHasa$278
Slide 19: Blood Purification Alternatives
Blood Purification Alternatives Blood Compatible Blood Incompatible HMCO Sorbents Sorbents Filters EMiC2 - Fresenius CytoSorb CPFA - Bellco CytoSorbents I.M.P.A.C.T - Hemolife SepteX - Baxter Oxiris - Baxter Theranova - Baxter 19
Slide 20: CytoSorb
CytoSorb 56,000+ Treatments 55 Countries Worldwide with E.U. United States Critical Care Cardiac Surgery Cardiac Surgery I REFRESH 2 Recently added Mexico and South Korea 2021 with partner, Fresenius Medical Care 20
Slide 21: CytoSorb Is a High Margin "Razorblade"
CytoSorb® Is a High Margin “Razorblade” • High margin “razorblade” fully compatible with existing installed base of “razor” blood pumps: Dialysis/CRRT, ECMO machines (ICU), heart-lung machines (OR) • Blended gross margins are >72%, expected to rise to ~80% on a quarterly basis in 2019, driven by vol
Slide 22: Direct Sales: Focused on 5 Countries
Direct Sales: Focused on 5 Countries CytoSorbents’ direct sales force focused on most major university and public hospitals in Germany, Austria, Switzerland, Belgium and Luxembourg with full Dr. Christian Steiner, MD reimbursement in Germany. German market alone is $1.0-1.5 B. Vice President – Sales
Slide 23: CytoSorb Distributed in 55 Countries
CytoSorb® Distributed in 55 Countries IntensivMed WMC 23
Slide 24: Four Major Partnerships, Potential for More
Four Major Partnerships, Potential for More Critical Care or Catheters Cardiac Surgery Renal Dialysis Blood Transfusion Pharma and Biotech Partnered with leading multinational corporations: Fresenius Medical Care, Terumo Cardiovascular, Biocon Ltd, and Dr. Reddy’s Laboratories * Companies listed her
Slide 25: Quarterly Product Sales
Quarterly Product Sales 26 Consecutive Quarters of Year-over-Year Sales Growth $5,400,000 $5,102,748 $5,245,555 Quarterly Product Sales $5,000,000 $4,433,296 $4,296,047 $4,000,000 $3,448,661 $3,041,012 $3,000,000 $2,596,133 $2,612,801 $2,143,116 $2,000,000 $1,852,670 $1,597,449 $1,495,590 $1,071,459
Slide 26: $20M in Annual Product Sales
$20M in Annual Product Sales Twenty-six consecutive quarters of year-over-year product sales growth, with a three-year compound growth rate of return (“CAGR”) of 71% $20.2M * $20,000,000 Annual Product Sales Trend Line $15,000,000 $13,381,853 Trend Line $10,000,000 $8,206,036 $5,000,000 $4,043,819 $
Slide 27: REFRESH 2-AKI Pivotal Trial Targets U.S. Approval
REFRESH 2-AKI Pivotal Trial Targets U.S. Approval • Heart disease is the leading killer worldwide, driving 1.5M open heart surgeries each year and fueled by the aging baby boomer generation • High risk invasive cardiac surgery generates inflammatory toxins (e.g. free hemoglobin and activated complem
Slide 28: German Govt Funding REMOVE Endocarditis Trial
German Govt Funding REMOVE Endocarditis Trial • Infective endocarditis (heart valve infection) occurs when bacteria seeds a heart valve from IV drug abuse and dirty needles, or from dental procedures • The incidence of endocarditis is rising due to the opiate crisis • Patients often require open hea
Slide 29: Expanded Label Targets Liver Failure and Trauma
Expanded Label Targets Liver Failure and Trauma Recently received European approval to expand the use of CytoSorb in liver disease to reduce bilirubin, and in trauma to reduce myoglobin – both very large markets • Liver disease • 850 million people suffer from chronic liver disease due to viral hepa
Slide 30: CAR-T Cell Immunotherapy and CRS
CAR-T Cell Immunotherapy and CRS • CAR-T cell cancer immunotherapy is a blood cancer treatment breakthrough. • However, ~40-50% of patients can develop severe, high grade cytokine release syndrome (CRS), a cytokine storm that can lead to rapid organ failure and potentially death • CytoSorb® was spec
Slide 31: Near-Term Potential Catalysts
Near-Term Potential Catalysts • Expected significant growth in sales and usage of CytoSorb, driven by: • Clinical data in more applications • Reimbursement in key territories • Investments in infrastructure and human capital to support our direct, distributor, and partner sales • 2019 blended produc
Slide 32: CytoSorbents Investment Summary
CytoSorbents Investment Summary CytoSorbents is strongly positioned and on track to have strong growth in 2019 and beyond • Established, well-run U.S. medtech but with a biotech profile, nearing critical mass • Strategically positioned to address some of the largest, most visible, unmet medical need
Slide 33: Contact: Dr. Phillip Chan, CEO
NASDAQ: CTSO Dr. Phillip Chan, MD, PhD – CEO pchan@cytosorbents.com